Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes

Human Vaccines

Volumn 2, Issue 2, 2006, Pages 60-67

  Guirakhoo, Farshad ^a   Kitckener, Scott ^a,e   Morrison, Dennis ^b   Forrat, Remi ^c   McCarthy, Karen ^a   Nichols, Richard ^a   Yoksan, Sutee ^d   Duan, Xiaochu ^a   Ermak, Thomas H ^a   Kanesa Thasan, Niranjan ^a   Bedford, Philip ^a   Lang, Jean ^c   Quentin Millet, Marie Jose ^c   Monath, Thomas P ^a  

^a Acambis   (United States)

^b Bio Kinetic Clinical Applications   (United States)

^c SANOFI PASTEUR   (France)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Chimeric yellow fever dengue 2; Immunogenicity; Live attenuated; Phase 1 trial; Safety

Indexed keywords

CHIMERIVAX; CREATINE KINASE; CROSS REACTING ANTIBODY; DENGUE VACCINE; GAMMA INTERFERON; LIVE VACCINE; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENGUE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE MASS; INJECTION SITE PAIN; LIVER TOXICITY; MALAISE; MALE; MYALGIA; PHOTOPHOBIA; PLAQUE FORMING CELL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SEROCONVERSION; SEROTYPE; SORE THROAT; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

EID: 33745237160     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2.2.2555     Document Type: Article

References (36)

1. Halstead SB. Epidemiology of dengue and dengue hemorrhagic fever. In: Gubler DJ, Kuno G, eds. Dengue and Dengue Hemorrhagic Fever. New York, NY: CABI Publishing, 1997a:23-44.
2. Gubier DJ. Dengue and dengue hemorrhagic fever: Its history and resurgence as a global public health problem. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. New York, NY: CABI Publishing, 1997:1-22.
3. Chambers TJ, Tsai TF, Pervikov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis: Report of a World Health Organization meeting. Vaccine 1997; 15:1494-502.
4. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. infection enhancement by nonneutralizing antibody. J Exp Med 1977; 146:201-17.
5. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
6. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology 1999; 257:1-6.
7. Saluzzo JF. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv Virus Res 2003; 61:419-43.
8. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monadi TP. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue tetravalent vaccine. J Virol 2001; 75:7290-304.
9. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59.
10. Guirakhoo F, Welrzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopolpoulos K, Catalan J, Monath TP. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74:5477-85.
11. Monath TP, McCarthy KM, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F. Clinical proof of principle for ChimeriVax™: Recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002a; 20:1004-18.
12. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in a Phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002b; 66:533-41.
13. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalem vaccine formulations in nonhuman primates. J Virol 2004; 78(9):4761-75.
14. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunology 1967; 99:291-6.
15. Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, Meager A, Ennis FA. Human T cell responses to dengue virus antigens: Proliferative responses and interferon γ production. J Clin Invest 1989; 83:506-13.
16. Mangada MM, Ennis FA, Rothman AL. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J Immunol Methods 2004; 284:89-97.
17. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy M, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax™-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response co challenge with inactivated Japanese Encephalitis antigen. J Infect Dis 2003; 188:1213-30.
18. Liu WJ, Wang XJ, Mokhonov W, Shi PY, Randall R, Khromykh AA. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile Virus involves blockage of STAT1 and STAT2 activation by nonstrutural proteins. J Virol 2005; 79:1934-42.
19. Guo JT, Hayashi J, Seeger C. West Nile Virus inhibits the signal transducuon pathway of alpha interferon. J Virol 2005; 79:1343-50.
20. Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg K. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J Med Virol 1985; 17(1):35-45.
21. Price WH. Sequential immunization as a vaccination procedure against dengue viruses. Am J Epidemiology 1968; 88:392-397.
22. Kanesa-thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R. Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 2003;69(Suppl6):32-38.
23. Kurane I, Okamoto Y, Dai LC, Zeng LL, Brinton MA, Ennis FA. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones. J Gen Virol 1995; 76:2243-9.
24. Dorrance WR, Frankel JW, Gordon I, Patterson PR, Schlesinger RW, Winter JW. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 1956; 77(5):352-64.
25. Carey DE, Myers RM, Rodrigues FM. Two episodes of dengue fever, caused by types 4 and 1 viruses, in an individual previously immunized against yellow fever. Am J Trop Med Hyg 1965; 14:448-50.
26. Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, Russell PK. Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status. J Infect Dis 1983; 148(6):1055-60.
27. Eckels KH, Kliks SC, Dubois DR, Wahl LM, Bancroft WH. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine. J Immunol 1985; 135(6):4201-3.
28. Guirakhoo F, Heinz FX, Kunz C. Epitope model of tick-borne encephalitis virus envelope glycoprotein E: Analysis of structural properties, role of carbohydrate side chain, and conformational changes occurring at acidic pH. Virology 1989; 169(1):90-9.
29. Mandl CW, Guirakhoo F, Holzmann H, Heinz FX, Kunz C. Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol 1989; 63(2):564-71.
30. Heinz FX. Epitope mapping of flavivirus glycoproteins. Adv Virus Res 1986; 31:103-68.
31. Heinz FX, Mandl CW, Guirakhoo F, Holzmann H, Tuma W, Kunz C. The envelope protein of tick-borne encephalitis virus and other flaviviruses: Structure, functions and evolutionary relationships. Arch Virol 1990; (Suppl 1):125-35.
32. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59:141-75.
33. Sweet BH, Wisseman Jr CJ., Kitaoka M, Tamiya T. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subject following administration of 17D yellow fever vaccine. Am J Trop Med Hyg 1962; 11:562-69.
34. Henderson BE, Cheshire PP, Kirya GB, LuIe M. Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys. Am J Trop Med Hyg 1970; 19:110-18.
35. + T cells to heterologous serorypes. J Immunology 2005; 175:2676-83.
36. Simmons CP, Dong T, Chau NV, Dung NTP, Chau TNB, Thao LTT, Dung NT, Hien TT, Rowland-Jones S, Farrar J. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005; 79:5665-75.